University of California, Los Angeles

Telix Pharmaceuticals announces primary results from Phase III ZIRCON trial published in The Lancet Oncology, showing TLX250-CDx (Zircaix®) highly accurate in detecting and characterizing clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs), potentially reducing unnecessary surgeries.

Arie Belldegrun, MD, launches Symbiotic Capital, a global life sciences credit firm with over $600 million in capital, to fund startups needing cash amidst sluggish equity markets. Symbiotic extends non-dilutive senior secure term loans, focusing on stability and maturity of companies, with investments ranging from $20 million to $200 million. The firm is disease agnostic and diversifies across life sciences sectors, aiming to align with companies' success through equity conversion and warrant positions.